A long-term, open-label, safety study of Kadian NT (morphine sulfate plus naltrexone hydrochloride extended release) capsules in subjects with chronic moderate to severe nonmalignant pain.

Trial Profile

A long-term, open-label, safety study of Kadian NT (morphine sulfate plus naltrexone hydrochloride extended release) capsules in subjects with chronic moderate to severe nonmalignant pain.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Sep 2013

At a glance

  • Drugs Morphine/naltrexone (Primary)
  • Indications Pain
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 05 Mar 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 12 Feb 2009 Results from 160 patients who completed the study were predented at the American Academy of Pain Medicine's 25th Annual Meeting in Honolulu, Hawaii, USA in January 2009.
    • 26 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top